רייאטאז 200 מג
bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.
רייאטאז 300 מג
bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 300 mg - atazanavir
אורנסיה 125 מג תת - עורי
bristol, myers squibb (israel) limited, israel - abatacept - תמיסה להזרקה - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.
אמפליסיטי 300 מג
bristol, myers squibb (israel) limited, israel - elotuzumab - אבקה להכנת תמיסה מרוכזת לעירוי - elotuzumab 300 mg/vial - elotuzumab
אמפליסיטי 400 מג
bristol, myers squibb (israel) limited, israel - elotuzumab - אבקה להכנת תמיסה מרוכזת לעירוי - elotuzumab 400 mg/vial - elotuzumab
אופדיבו
bristol, myers squibb (israel) limited, israel - nivolumab - תרכיז להכנת תמיסה לאינפוזיה - nivolumab 10 mg/ml - nivolumab
איקסמפרה 15 מ"ג
bristol-myers squibb (israel) limited - ixabepilone 15 mg - powder for concentrate for infusion - ixabepilone - ixempra is indicated for the treatment of inoperable locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy:in combination with capecitabine in patients failing prior therapy with a taxane and an anthracycline or for whom further anthracycline therapy is not indicated.as monotherapy in patients failing prior therapy with taxanes, capecitabine and anthracyclines or for whom futher anthracycline therapy is not indicated.
איקסמפרה 45 מ"ג
bristol-myers squibb (israel) limited - ixabepilone 45 mg - powder for concentrate for infusion - ixabepilone - ixempra is indicated for the treatment of inoperable locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy:in combination with capecitabine in patients failing prior therapy with a taxane and an anthracycline or for whom further anthracycline therapy is not indicated.as monotherapy in patients failing prior therapy with taxanes, capecitabine and anthracyclines or for whom further anthracycline therapy is not indicated.
תלידומיד בי אם אס 50 מג כמוסות קשיחות
neopharm ltd - thalidomide - קפסולה קשיחה - thalidomide 50 mg - thalidomide
אליקוויס 2.5 מג
pfizer pharmaceuticals israel ltd - apixaban - טבליות מצופות פילם - apixaban 2.5 mg - apixaban - apixaban - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age? 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ? ii).